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Abstract
The matrix metalloproteinases (MMP) are a family of 23 enzymes in man. These enzymes were originally described as cleaving
extracellular matrix (ECM) substrates with a predominant role in ECM homeostasis, but it is now clear that they have much wider
functionality. Control over MMP and/or tissue inhibitor of metalloproteinases (TIMP) activity in vivo occurs at different levels
and involves factors such as regulation of gene expression, activation of zymogens and inhibition of active enzymes by specific
inhibitors. Whilst these enzymes and inhibitors have clear roles in physiological tissue turnover and homeostasis, if control of their
expression or activity is lost, they contribute to a number of pathologies including e.g. cancer, arthritis and cardiovascular disease.
The expression of many MMPs and TIMPs is regulated at the level of transcription by a variety of growth factors, cytokines and
chemokines, though post-transcriptional pathways may contribute to this regulation in specific cases. The contribution of epigenetic
modifications has also been uncovered in recent years. The promoter regions of many of these genes have been, at least partly,
characterised including the role of identified single nucleotide polymorphisms. This article aims to review current knowledge across
these gene families and use a bioinformatic approach to fill the gaps where no functional data are available.
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. Introduction
The matrix metalloproteinases (MMPs) are a family
f 23 enzymes in man. These enzymes were originally
escribed as cleaving extracellular matrix (ECM) sub-
trates with a predominant role in ECM homeostasis,
ut it is now clear that they have much wider func-
ionality. Such functions include: opposing effects on
ngiogenesis via matrix degradation but also release of
ngiogenesis inhibitors (via digestion of e.g. plasmino-
en to generate angiostatin, and type XVIII collagen to
enerate endostatin); regulation of cell growth via cleav-
ge of cell surface-bound growth factors and receptors,
elease of growth factors sequestered in the ECM or inte-
rin signalling; regulation of apoptosis via release of
eath or survival factors; alteration of cell motility by
evealing cryptic matrix signals, or cleavage of adhe-
ion molecules; effects on the immune system and host
efense; modulation of the bioactivity of chemokines
Cauwe, Van den Steen, & Opdenakker, 2007).
Traditionally, the MMPs have been subdivided into
ollagenases, gelatinases, stromelysins, and membrane-
ype MMPs, according to their substrate specificity,
rimary structure and cellular location. However, several
ore recently discovered enzymes do not fit easily into
hese classifications and alternatives based on domain
tructure, activation mechanism and cellular location
ave been suggested e.g. (Brinckerhoff & Matrisian,
002). The MMPs have a common domain structure with
signal peptide, a propeptide, a catalytic domain, a hinge
egion and, in the majority of cases, a C-terminal domain.
he propeptide contains an invariant Cys residue (in
ll but MMP-23), which ligates the active site zinc ion
o maintain latency; the catalytic domain contains a
EXGHXXGXXH zinc-binding sequence characteris-
ic of the metzincin superfamily of proteinases, followed
y an invariant methionine which is involved in a
tructural feature called the ‘Met-turn’. In all family
embers except MMP-7(matrilysin-1), MMP-23 (CA-
MP) and MMP-26 (matrilysin-2), a hinge region
inks to a haemopexin-like C-terminal domain which is
hought to be involved in substrate specificity and bind-
ng of inhibitors. Individual MMPs contain variations
n this theme e.g.: membrane-type (MT)-MMPs (MMPs
4–17, -24 and -25) have either a transmembrane domain
nd cytoplasmic tail at the C-terminus (MMP 14–16 and
24) or are GPI-anchored (MMP-17 and -25). In com-
on with MMP-11, -21, -23 and -28, the MT-MMPslso contain a potential furin-cleavage site within the
ropeptide allowing activation prior to secretion. The
elatinases (MMP-2 and -9) have an insert of three-
bronectin type II repeats in the catalytic domain andemistry & Cell Biology 40 (2008) 1362–1378 1363
MMP-9 also has a collagen-like sequence at one end of
the catalytic domain.
A family of four specific inhibitors, the TIMPs, has
been described (Baker, Edwards, & Murphy, 2002).
Whilst the ability of the four TIMPs to inhibit MMPs is
largely promiscuous, a number of functional differences
have been noted, e.g. TIMP-2, -3 and -4, but not TIMP-
1, are effective inhibitors of the MT-MMP subclass and
MMP-19.
Control over MMP and/or TIMP activity in vivo
occurs at different levels and involves factors such as
regulation of gene expression, activation of zymogens
and inhibition of active enzymes by specific inhibitors.
Many MMPs and TIMPs are regulated at the level of
transcription by a variety of growth factors, cytokines
and chemokines e.g. (Yan & Boyd, 2007).
1.1. MMP promoter analysis and gene expression
In addition to showing characteristic patterns of
tissue- and developmental stage-specific patterns of
expression (Nuttall et al., 2004), particular cell types dis-
play signal-dependent activation and repression of MMP
and TIMP gene transcription involving the mitogen-
activated protein kinase (MAPK), nuclear factor-B
(NFB) and Smad-dependent pathways (Borden &
Heller, 1997; Overall & Lopez-Otin, 2002; Vincenti &
Brinckerhoff, 2002; Westermarck, Li, Kallunki, Han,
& Kahari, 2001). Most MMPs and TIMPs respond to
stimuli at the transcriptional level with delayed kinetics
over a timeframe of several hours and require ongoing
translation (Sampieri et al., 2008). This suggests that
they are components of genetic programmes such as the
wound repair response, in which they are downstream
targets of immediate-early (IE) response genes that are
induced within minutes of cell stimulation and in the
absence of new protein synthesis. Chief among these IE
genes are the Fos and Jun genes that comprise activa-
tor protein-1 (AP-1) and at the level of the individual
gene promoter, a promoter-proximal AP-1 site was the
first cis-acting element to be implicated in the induction
of MMP1 expression (Angel et al., 1987). A number of
MMP promoters have now been at least partly character-
ized, revealing a variety of functional cis-acting elements
(e.g. AP-1, PEA3, Sp1, Tcf/Lef-1, NFB, RARE).
A recent review on MMP gene expression (Yan
& Boyd, 2007) uses the basic promoter conforma-
tion to assign MMPs to one of three groups (i) those
which contain TATA boxes at around −30 bp with AP-
1 sites around −70 bp (MMP1, MMP3, MMP7, MMP9,
MMP10, MMP12, MMP13, MMP19 and MMP26); (ii)
those which contain a TATA box, but no promoter-
f Bioch1364 I.M. Clark et al. / The International Journal o
proximal AP-1 site (MMP8, MMP11 and MMP21); and
(iii) those with no TATA box nor proximal AP-1 (MMP2,
MMP14 and MMP28).
A bioinformatic analysis across the MMP family
proves problematic since many known functional sites,
including e.g. the promoter-proximal PEA3 site in
MMP1, are non-canonical. Furthermore, the transcrip-
tion start point is unknown for many MMPs and can
only be inferred by examination of the longest known
mRNA. However, using such methodology to analyse
1 kb of upstream sequence for each MMP and TIMP
gene (Fig. 1) addsMMP20 to group one (AP-1 and TATA
containing); MMP15 and MMP27 to group two (TATA
but no AP-1); and MMP16, MMP17, MMP23, MMP24
and MMP25 to group three (no TATA, no AP-1). Of
these, the assignment of the promoter region forMMP23,
MMP24 andMMP25 is most tenuous from the databases.
As amongst most multi-gene families, the MMPs can be
co-regulated under a variety of stimuli, and the above
classification is certainly useful, with e.g. many of the
group 1 genes (TATA box and proximal AP-1 site)
induced by interleukin-1 (IL-1), tumour necrosis factor
alpha (TNF) or phorbol ester treatment in many cell
types. However, it may disguise the inherent complex-
ity which underlies the regulation of these genes and the
subtlety by which differential regulation can be achieved.
Even accepting the promoter-proximal AP-1 site as
a major mediator of regulation, specificity across genes
or cell types remains possible. Firstly, the composition
of the AP-1 complex itself may determine the response:
early work indicated that c-Jun was able to induceMMP1
minimal promoter constructs (in F9 cells which lack
endogenous AP-1) whilst JunB was reported as a repres-
sive factor in the absence of c-Fos, but an inducing
factor in the presence of c-Fos (Chiu, Angel, & Karin,
1989). The influence of the promoter-proximal AP-1
site may also change dependent on the construct under
assay. Originally examined in the rabbit MMP1 pro-
moter, a second, non-canonical AP-1 site was identified
at −186 bp which altered the response of the promoter
to phorbol ester and removed some of the dependency
on the promoter-proximal (−77 bp) AP-1 site. The AP-
1 complex at both sites contained c-Fos and JunD, but
Fra-2 was only present at the −77 bp site (White &
Brinckerhoff, 1995). Other proteins may interact with
Fig. 1. Bioinformatic analysis of MMP and TIMP genes. The transcription
evidence in the literature or (ii) inferred from the longest reported mRNA (Ense
where possible (the latter method appeared particularly tenuous for MMP23,
was then analysed using MatInspector (Genomatix, http://www.genomatix.de
protein 2 (AP-2), erythroblastosis twenty-six (Ets), polyoma enhancer elem
acid response element (RAR/RXR), retinoid X response element (RXRE/RX
activator of transcription (STAT) and T-cell factor/lymphoid enhancer factor (emistry & Cell Biology 40 (2008) 1362–1378
the AP-1 site. Nucleolin was recently identified as such
a protein, and chromatin immunoprecipitation (ChIP)
shows it binding in the vicinity of the AP-1 site within the
MMP13 promoter. Moreover, overexpression of nucle-
olin can repress transactivation of the MMP13 promoter
transiently transfected into HeLa cells (Samuel, Twizere,
Beifuss, & Bernstein, 2008).
Further complexity can be generated by the juxtapo-
sition of transcription factor binding sites or indeed the
presence of composite sites. Fra-1 alone was recently
shown to be unable to transactivate the human MMP9
promoter in MCF7 cells. Promoter sequence analysis
showed a STAT3 binding site in juxtaposition with the
AP-1 site and indeed, the co-transfection of Fra-1 and
Stat3C strongly transactivated the promoter. A complex
of c-Jun/Fra-1 and Stat3 was identified on this region
of the promoter (Song et al., 2008). In the MMP1 pro-
moter, the proximal AP-1 site has been reported to
be within a composite element with at least a perox-
isome proliferator-activated receptor gamma (PPAR)
consensus whereby PPAR and AP-1 bind the element
in a mutually exclusive manner (Fahmi et al., 2002;
Francois et al., 2004). Burrage, Huntington, Sporn, and
Brinckerhoff (2007) extended this observation to show
that the promoter-proximal AP-1 site in the MMP1 and
MMP13 promoters overlap a degenerate direct repeat
(DR)1 nuclear hormone response element with similar
elements found more distally in other MMP genes. Our
own computer analysis in Fig. 1 shows such composite
AP-1/RAR-RXR elements in the upstream 1 kb regions
of at least MMP7, MMP9 and MMP19 genes.
Interestingly, MMP11 appears unique amongst char-
acterised MMP promoters in having a functional retinoic
acid response element (DR1-RARE) in its proximal pro-
moter mediating its induction by retinoic acid. Two
upstream DR2-RAREs are also present and appear to
contribute to basal expression from the gene promoter
(Ludwig, Basset, & Anglard, 2000). Bioinformatic anal-
ysis suggests several MMP and TIMP promoters contain
canonical retinoic acid or retinoid X receptor response
elements within the upstream 1 kb region (MMP1,
MMP2, MMP7, MMP9, MMP11, MMP13, MMP14,
MMP17, MMP19, MMP21, MMP23, MMP26, TIMP1,
TIMP3 and TIMP4). Interestingly, these are almost all
of the DR1 spacing, the most promiscuous of such sites,
start point (tsp) of each gene was either (i) taken from experimental
mbl, http://www.ensembl.org/) with confirmation from other databases
MMP24 and MMP25 genes). 1 kb of upstream (promoter) sequence
/) to search for consensus sites for activator protein 1 (AP-1), activator
ent A3 (PEA3), GC box, nuclear factor kappa B (NFB), retinoic
R), Runt-related transcription factor 2 (Runx2), signal transducer and
Tcf/Lef).
I.M. Clark et al. / The International Journal of Biochemistry & Cell Biology 40 (2008) 1362–1378 1365
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Fig. 1. (Continued ).
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nown to recruit at least RAR/RXR, RXR/RXR, and
PAR/RXR in vitro (Ijpenberg et al., 2004; Durand,
aunders, Leroy, Leid, & Chambon, 1992; Mader, Leroy,
hen, & Chambon, 1993; Mangelsdorf et al., 1991).
In many MMP promoters containing proximal AP-1
ites, a PEA3-binding consensus is found in close prox-
mity upstream, and these sites act cooperatively. Again,
ince many of these sites are able to bind multiple Ets fac-
ors, they can mediate specificity. MMP1 expression was
hown to be differentially regulated by different struc-
ural classes of Ets factors e.g. Ets1, ErgB/Fli-1 and Pu1.
ts1 increased basal activity of 3.8 kb MMP1 promoter,
hilst the others had no effect. Ets1 augmented trans-
ctivation by both c-Jun and JunB, ErgB augmented
ransactivation only via JunB, whilst Pu1 repressed
nduction by both c-Jun and JunB. As above, all of these
ffects were dependent on the promoter-proximal AP-1
ite (Westermarck, Seth, & Kahari, 1997).
Many MMPs have multiple GC boxes in their proxi-
al promoters which bind Sp1 and Sp3 and potentially
ther GC-binding proteins. The MMPs without other
bvious promoter features are generally expressed in
more constitutive fashion e.g. MMP2 and MMP14.
ndeed, the promoter-proximal (−92 bp) Sp1 site in the
MP14 promoter is crucial in maintaining expression
f this gene since its mutation reduces promoter activity
y approximately 90% (Lohi, Lehti, Valtanen, Parks, &
eski-Oja, 2000). Our bioinformatic analysis would add
MP15, MMP16, MMP17, MMP23, MMP24, MMP25,
IMP2 and possibly MMP27 and TIMP3 to this list.
owever, these genes are still clearly regulated and a
umber of promoter dissections show responsive sites
utside of the GC boxes.
In astroglioma cells, an Sp1 site at −91/−84 bp and
n AP-2 site at −61/−53 bp mediate activation of the
MP2 gene by Sp1, Sp3 and AP-2 factors (Qin, Sun, &
enveniste, 1999). MMP2 was also shown to be a target
f p53 transactivation via a p53 site at −1659/−1622 bp
Bian & Sun, 1997; Yan, Wang, & Boyd, 2002). Stat3
as also been linked with the induction of MMP2 in
ells from metastatic melanoma (Xie et al., 2004) via a
onsensus site in the promoter at −617/−610 bp. Other
tat3 binding sites have been identified in theMMP2pro-
oter within the upstream enhancer sequence (denoted
E-1 in the rat promoter) (En-Nia et al., 2002). Inter-
stingly, in an ischaemia model, Fos and Jun proteins
ere shown to bind to a non-canonical AP-1 site in
he MMP2 promoter, with p53 binding to an adjacent
nhancer site (RE-1) and NFAT-c2 binding within intron
. Deletion of the former or substitution of the latter
ed to decreased expression in transgenic mice express-
ng beta-galactosidase from an MMP2 promoter/intronemistry & Cell Biology 40 (2008) 1362–1378 1367
1 construct (Lee et al., 2005). The upstream (−1394 bp)
AP-1 site had previously been described as important
for the induction of MMP2 expression by hypoxia in
cardiac cells with binding of Fra1-JunB or FosB-JunB
heterodimers (Bergman et al., 2003). This belies the idea
that MMP2 is constitutively produced and not regulated
by AP-1 complexes.
Egr1, like Sp1 and Sp3, binds GC-rich sequences,
and both specificity of binding to cognate sites and cross-
competition has also been demonstrated (Al-Sarraj, Day,
& Thiel, 2005)). Egr1 has been implicated in the regula-
tion of e.g.MMP14 in cells cultured in three-dimensional
matrices (Barbolina, Adley, Ariztia, Liu, & Stack, 2007;
Haas, Stitelman, Davis, Apte, & Madri, 1999) orMMP14
and MMP2 by cigarette smoke in lung fibroblasts (Ning
et al., 2007).
In mesangial cells,MMP14 expression is regulated by
proximal and overlapping Sp1- and Sp1/Egr1-binding
sites as well as a more distal site for NFATc1 (Alfonso-
Jaume, Mahimkar, & Lovett, 2004).
NFB is known to regulate many MMP genes
(Vincenti & Brinckerhoff, 2007). An NFB site was
originally identified in the MMP9 promoter (He, 1996)
with a potential role in TNF induction of the gene.
NFB was also shown as essential for the synergis-
tic induction of MMP9 expression by growth factors
and inflammatory cyokines (Bond, Fabunmi, Baker, &
Newby, 1998). MMP1 is also regulated by NFB, with
a non-canonical site binding NFB1 at −2886 bp in
the rabbit promoter (Vincenti, Coon, & Brinckerhoff,
1998). In other MMP genes induced by NFB, no func-
tional NFB sites have been identified: again, such sites
could simply be non-canonical or some of these effects
may be indirect. A number of MMP and TIMP proximal
promoters show canonical NFB sites on sequence anal-
ysis (MMP1, MMP2, MMP8, MMP9, MMP11, MMP13,
MMP14, MMP15, MMP17, MMP19, MMP23, MMP25,
MMP26, TIMP2 and TIMP4).
MMP7 was the first MMP shown to be regulated by
Wnt signalling being the target of beta-catenin regu-
lation via Tcf/Lef-1. The human MMP7 promoter has
two upstream Tcf/Lef-1 binding sites at −109 bp and
−194 bp which mediate transactivation of the promoter
by beta-catenin (Gustavson, Crawford, Fingleton, &
Matrisian, 2004). Tcf/Lef-1 synergises with other fac-
tors, particularly those of the PEA3 family, to drive
expression of MMP7 in colorectal tumours (Crawford
et al., 2001). MMP14 has also been identified as a
target of beta-catenin signalling in colorectal cancers
with a Tcf/Lef-1 site at −1169/−1163 bp mediating
this effect (Takahashi, Tsunoda, Seiki, Nakamura, &
Furukawa, 2002). MMP26, a poorly expressed gene
f Bioch1368 I.M. Clark et al. / The International Journal o
in most cell types, is also reported to have a Tcf
motif in its promoter (Marchenko, Marchenko, Leng, &
Strongin, 2002). Bioinformatic analysis of the upstream
1 kb region reveals canonical Tcf/Lef sites in MMP1,
MMP3, MMP7, MMP8, MMP9, MMP10, MMP14,
MMP19, MMP21, MMP23, MMP26, MMP27, MMP28
and TIMP4. Thus, these are common sequences within
these genes, though most are not functionally verified.
The MMP13 gene is regulated in part by a promoter-
proximal Runx2 (aka Cbfa1, AML3) site which directs
its expression in osteoblasts and hypertrophic chondro-
cytes (Jimenez et al., 1999; Porte et al., 1999). In stably
transfected chondrocytic cell lines, IL-1 inducesMMP13
expression via both promoter-proximal AP-1 and Runx2
sites (Mengshol, Vincenti, & Brinckerhoff, 2001). Trans-
genic mice expressing beta-galatosidase from −148 bp
of the rat MMP13 promoter, containing both the AP-1
and Runx2 sites, display expression in bone, teeth and
skin at levels that are elevated compared to transgenic
lines in which these sites are mutated. This shows that the
promoter-proximal AP-1 and Runx2 sites in the MMP13
promoter are necessary and sufficient to direct expres-
sion in these tissues in vivo, though may not be sufficient
to recapitulate all aspects of endogenousMMP13 expres-
sion (Selvamurugan et al., 2006). Aside from MMP13,
MMP9 expression is also regulated by Runx2 via a
promoter-proximal consensus and three non-canonical
upstream Runx2 sequences (Pratap et al., 2005). This
fits with a role for MMP-9 in endochondral ossification
revealed by the growth plate phenotype of theMMP9null
mouse (Ortega, Behonick, & Werb, 2004). Interestingly,
bioinformatic analysis shows canonical Runx2 sites in
the upstream 1 kb regions of MMP1, MMP7, MMP8,
MMP13, MMP17, MMP21, MMP26, TIMP1, TIMP2
and TIMP3 though, of course, these await functional
analysis. Runx2 may direct expression in hypertrophic
chondrocytes and osteoblasts, but MMP13 and indeed
most MMPs do not show true tissue specificity. MMP20
is the prime example, being expressed almost exclusively
in tissues of the tooth. The bioinformatic analysis of 1 kb
of upstream sequence (above) shows two canonical AP-
1 sites and this has been backed up experimentally in
a recent paper which shows four potential AP-1 sites
within 1.5 kb of promoter with three of them binding
c-Jun (Zhang, Li, Chi, Chen, & Denbesten, 2007).
Similar to the group 1MMPs, TIMP1 has a promoter-
proximal AP-1 site (though non-canonical) with a
neighbouring PEA3 site as major mediators of transcrip-
tion. Logan, Garabedian, Campbell, and Werb (1996)
demonstrated that the proteins binding to the AP-1 site
at −92/−86 bp may interact with those at the PEA-3
site at −79/−74 bp to enhance transcription driven fromemistry & Cell Biology 40 (2008) 1362–1378
the whole element. Interestingly, Phillips, Sharma, Leco,
and Edwards (1999) showed that the TIMP1 AP-1 site
was also able to bind a single-stranded DNA-binding
protein whereas the (canonical)MMP1AP-1 site did not.
TIMP1 is both constitutively expressed and inducible
and this may explain its lack of a TATA box, multi-
ple transcription start points and GC boxes. A number
of other consensus sites have also been shown to be
functional within the promoter (e.g. upstream TIMP
element-1 which binds Runx1 and Runx2 proteins at
−62/−52 bp (Bertrand-Philippe et al., 2004; Trim et al.,
2000), a hypoxia response element at −27/−23 bp, an
Egr1 site at −33 bp (Aicher et al., 2003). The TIMP1
gene differs from other TIMP family members in having
a short first exon which is transcribed, but not translated,
with the translation start site located on exon 2. There
is evidence that regulatory sequences exist within the
first intron of the Timp1 gene. Flenniken and Williams
(1990) found that a construct containing around 1.3 kb of
murine TIMP-1 5′ flanking sequence, exon 1 and most of
intron 1 linked to a lacZ reporter in transgenic mice was
sufficient to reproduce the spatial and temporal expres-
sion of the Timp1 gene in developing mouse embryos. In
contrast to this, transgenic mice carrying lacZ linked to
2.7 kb of Timp1 5′ flanking sequence, but lacking intron
1, display a subset of the correct pattern of expression
(e.g. appropriate expression in the developing vertebral
column, and absence in the liver), but also inappropri-
ate expression of the reporter in sites such as the spinal
cord (D.R. Edwards, unpublished data). Thus, sequences
within intron 1 are likely to repress Timp1 gene expres-
sion and this was demonstrated in vitro by Dean, Young,
Edwards, and Clark (2000) who showed at least Sp1,
Sp3 and Ets-factor binding to a repressive cis-acting
sequence in the intron.
The TIMP2 gene has a TATA box at around −30 bp,
though still displays multiple transcription start points.
It contains several Sp1 sequences, characteristic of a
housekeeping gene, two AP-2 sites, three PEA3 sites
and an AP-1 site (at −281 bp) (Hammani et al., 1996).
Interestingly, the AP-1 site does not lead to induction of
the TIMP2 promoter by phorbol ester in the same way
as does the more proximal site in the TIMP1 promoter.
However, insertion of an AP-1 consensus at position
−71 bp in the TIMP2 gene generates phorbol induc-
tion of the mutant. An Sp1 and Sp3-binding motif at
−107/−98 bp cooperates with an inverted CCAAT box,
binding NF-Y, at 73/−69 bp for both basal expression
from the TIMP2 promoter and its induction by cAMP
(Zhong, Hammani, Bae, & DeClerck, 2000).
The murine Timp3 gene has a TATA box and single
transcription start point. The proximal (approximately
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00 bp) promoter has three GC boxes, and more dis-
ally (−600 to −2000 bp) contains six AP-1 consensus
equences, two NFB sites and two p53 sites (Sun et
l., 1995). This structure is reflected in the activity
f promoter fragments in transient transfection exper-
ments where a −2846/ + 58 bp construct is inducible
y TNF or phorbol ester, but a −491/ + 23 bp con-
truct is not inducible by these factors. Interestingly, this
roup also found that Timp3 is poorly expressed in a
umber of neoplastic cell lines and that the promoter
n these lines can be hypermethylated or hypomethy-
ated. Treatment with a DNA methyl transferase inhibitor
eads to reexpression of Timp3 only in the line display-
ng promoter hypermethylation. Similarly, the human
IMP3 promoter displays a promoter-proximal GC-rich
egion which is capable of mediating basal expression,
ith regions further upstream mediating serum induction
Wick et al., 1995).
Amongst the TIMPs, TIMP4 displays tight tissue
pecificity, predominantly in the heart and brain (Leco et
l., 1997). The TIMP4 promoter has no TATA box, but
oes contain an initiator sequence and the gene displays
ultiple transcription start points (Young et al., 2002).
he proximal promoter contains an inverted CCAAT
ox and an Sp1 site. Mutation of the former causes
n increase in reporter expression. More significantly,
utation of either the initiator sequence or the Sp1 site
bolishes reporter expression completely.
.2. Acetylation and MMP expression
Acetylation is a post-translational covalent protein
odification that is strongly implicated in transcriptional
egulation. Histones were the first proteins identified
s showing variable acetylation status. Simplistically,
cetylation weakens the histone:DNA interaction, allow-
ng access to transcription factors and therefore generally
ssociated with gene activation. This has been fol-
owed by a plethora of molecules ranging from
tructural proteins, intracellular signaling molecules,
uclear membrane receptors and transcription factors
hat have been shown to be acetylated. Acetylation, like
hosphorylation, is a reversible modification with acetyl
roups added by a family of histone acetyl transferase
nzymes (HATs) and removed by histone deacetylases
HDACs). Inhibitors of the so-called classical HDACs
HDACs 1–11) are in development as cancer therapeutics
s they have potent anti-proliferative and pro-apoptotic
ctivities in cancer cells.
The role of acetylation in the expression of MMPs has
een probed for a number of genes. An early report of
cetylation impacting upon MMP gene expression wasemistry & Cell Biology 40 (2008) 1362–1378 1369
by Pender, Quinn, Sanderson, and MacDonald (2000)
working with human fetal mucosal mesenchymal cells.
In this paper, HDAC inhibitors (HDACi) were shown
to enhance IL-1 or TNF induction of MMP3 and to
repress IL-1 or TNF induction of MMP1 and MMP9
both at the mRNA and protein level. No effect of these
HDACi was seen on unstimulated levels of any MMP
examined, and no effect was seen on MMP2 or TIMP1,
neither of which was induced by IL-1 or TNF. From
these data, it is likely that the effect of HDACi is on the
signaling pathways induced by these proinflammatory
cytokines, rather than on the MMP genes themselves,
though this is currently unknown. It is interesting that the
same HDACi can lead to enhancement or repression of
an induced MMP (compare MMP3 to MMP1 and MMP9
above): this might suggest that there are differences in
the pathways by which IL-1 or TNF induce MMP3
compared to MMP1 and MMP9 or that there are subtle
differences in the impact of HDACi on e.g. NFB that
are gene specific.
Ailenberg and Silverman (2002, 2003) then described
that HDAC inhibitors could repress MMP2 gene expres-
sion at the mRNA level in NIH 3T3 cells. In this cell
line, TSA did not alter expression of either MMP14 or
TIMP2, factors known to be involved in proMMP-2 acti-
vation.MMP2 expression in the human fibrosarcoma cell
line HT1080 was much less sensitive to HDACi treat-
ment, even at high concentrations. Similarly, Kaneko et
al. (2004) demonstrate both reduced invasion through
Matrigel, and reduced MMP expression and activity, in
response to HDACi. In human liver cancer cell lines,
treatment with HDACi reduced activity of MMP-2 and
MMP-9 and expression of MMP1. The expression of
TIMP1 and TIMP2 was unaffected. Since the effect of
HDACi on MMP levels was similar to that of interferon-
, the authors speculate on cross-talk or commonality
between the signalling pathways activated by these fac-
tors.
These papers do not dissect in detail the mechanism(s)
by which HDACi impact upon MMP gene expression in
terms of the HDAC involved, nor in terms of the num-
ber of MMPs affected by an HDACi. Yan, Wang, Toh,
and Boyd (2003) showed that the metastasis-associated
gene MTA1, a component of the NuRD repressor com-
plex binds to −650/−450 bp of the MMP9 promoter,
recruiting HDAC2 and decreasing histone acetylation
and thereby gene expression. An HDAC independent
mechanism involving the Mi-2 nucleosomal remod-
elling activity was also postulated. Martens, Verlaan,
Kalkhoven, and Zantema (2003) considered the induc-
tion of the MMP1 gene in T98G human glioblastoma
cells by a combination of serum and phorbol ester. This
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combination gives a potent induction of MMP1 expres-
sion at the mRNA level between 90 min and 2 h with a
maximal induction at 4–6 h. These authors used ChIP to
identify factors recruited to the MMP1 promoter in this
system and examined the kinetics of histone modifica-
tions occurring with induction of the gene. Acetylation
per se is insufficient to induce MMP1 expression in these
cells since HDACi had no effect on MMP1 expression
despite an increase in local H3 acetylation at the MMP1
promoter. It appears that upon activation with serum and
phorbol ester, c-Jun, c-Fos, TBP, RNAPII and SET9
assemble on the MMP1 promoter and histones at this
location are dimethylated (and eventually trimethylated).
p300 and RSK2 are then recruited which correlates
with an increase in acetylation and phosphorylation
of histones at the MMP1 promoter. Finally, Swi/Snf,
an ATP-dependent nucleosome remodeling complex is
recruiting allowing initiation of transcription.
In a similarly detailed dissection of events at the
promoter, Ma, Shah, Chang, and Benveniste (2004)
examined PMA induction of the MMP9 gene in HeLa
cells. Increased MMP9 mRNA is apparent by 2 h of
PMA treatment and becomes maximal at 6 h. An NFB
site, two AP-1 sites and an Sp1 site in the MMP9
promoter are all involved in induction. Micrococcal
nuclease digestion demonstrates that the MMP9 pro-
moter is in a regular nucleosomal array, and chromatin
remodeling is necessary for MMP9 transcription. This
latter is elegantly proven by using a Brg1-deficient cell
line (SW-13 cells); Brg1 is the ATPase subunit of the
Swi/Snf complex. In these cells, MMP9 is not expressed
on PMA stimulation, but transfection with Brg1 (but
not an ATPase-null mutant) rescued responsiveness of
MMP9 expression to PMA. ChIP experiments demon-
strated recruitment of AP-1 factors, NFB factors and
Sp1 at appropriate time points, and modifications in
histone acetylation, phosphorylation and methylation.
MTA, a specific protein methyltransferase inhibitor,
suppressed PMA-induced MMP9 expression, whilst
HDACi enhance PMA-induced MMP9 expression.
These authors also demonstrated that both HDAC1- and
HDAC3-containing complexes occupy the MMP9 pro-
moter in unstimulated HeLa cells, but that these are
removed upon stimulation with PMA. This was rein-
forced by the repressive effects of HDAC1 or HDAC3
(but not HDAC2 or HDAC4) on PMA-induced MMP9.
Both of these papers (Ma, Shah et al., 2004; Martens
et al., 2003) demonstrate a coordinated cascade of cell
signaling, histone modifications, nucleosome remodel-
ing and recruitment of transcription factors. This may
be cell type, species, or stimulus-specific. Ma, Chang
et al. (2004) also showed that Brg-1, the ATPase sub-emistry & Cell Biology 40 (2008) 1362–1378
unit of the Swi/SNF complex impacts upon MMP2 gene
expression. Using SW-13 cells and adding back Brg-1
demonstrated that this factor is required for recruiting
Sp1, AP-2 and RNA polymerase II to the MMP2 pro-
moter, with Sp3-binding decreased.
Using HDAC7 null mice, Chang et al. (2006)
show that HDAC7 maintains vascular integrity in early
embryogenesis via repression of MMP10. HDAC7 (or
indeed HDAC5) binds to MEF2, shown to be a tran-
scriptional activator of MMP10 to repress expression of
the latter.
Young, Lakey et al. (2005) show that HDACi block
IL-1/OSM-induced cartilage resorption in an explant
model in a dose-dependent manner at the level of both
proteoglycan and collagen release. This was accom-
panied by a reduction in activity and activation of
procollagenases in the conditioned medium and a
similar reduction in gelatinase activity. In cultured
primary chondrocytes, HDACi repressed the IL-1/OSM-
induction of collagenolytic MMPs (MMP1 and 13). In
SW1353 chondrosarcoma cells, the majority of metal-
loproteinase genes that were robustly induced by the
IL-1/OSM combination, were then repressed by the
HDACi; these were MMP1, MMP3, MMP7, MMP8,
MMP10, MMP12 and MMP13. The basal expression
of three metalloproteinase genes (MMP17, MMP23 and
MMP28) was also induced by HDACi. These data sug-
gest that HDACi impact upon IL-1/OSM signaling to
repress induced levels of metalloproteinases and that the
basal expression of a number of metalloproteinases is
responsive to HDACi. There is no overlap between these
groups, which may point to mechanisms/pathways by
which groups of genes are coexpressed in these enzyme
families.
At the simplest level, acetylation of histones at a gene
promoter may increase access to cis-acting sequences
by their cognate transcription factors. However, acetyla-
tion and deacetylation of signaling pathway components
and transcription factors themselves makes the situation
complex. This complexity is undoubtedly increased by
cell specific differences in some of these events.
Young, Billingham, Sampieri, Edwards, and Clark
(2005) detail the differential effects of HDACi on
the TIMP1 gene dependent on the stimulus used to
induce the gene. HDACi enhance PMA-induced TIMP1
expression but repress TGF-induced TIMP1 expres-
sion. Interestingly, the dose (of HDACi)-response curves
for these two effects are markedly different. This strongly
suggests that different HDACs are the target of HDACi
in each case. Furthermore, the effect of HDACi on the
endogenous TIMP1 gene can be reiterated at the level
of transient transfection of promoter-reporter constructs.
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his perhaps suggests that their effects are more likely
ediated by acetylation of signaling molecules or tran-
cription factors rather than histones.
As discussed above, many inducible MMP genes con-
ain promoter-proximal AP-1 sites that are key features
f their inducibility. In order for c-Jun to activate tar-
et gene transcription, it requires phosphorylation by the
un-N-terminal kinase (JNK) at serines 63/73 and thre-
nines 91/93. An ‘activation by de-repression’ model
as been proposed for the mechanism by which phos-
horylation activates c-Jun. Thus, c-Jun phosphorylation
ediates dissociation of an inhibitory complex which is
ssociated with HDAC3. Subsequent to this dissocia-
ion, c-Jun can go on to activate target gene expression
hether or not it is phosphorylated. c-Jun can also be
ctivated by an increase in cellular levels of c-Jun pro-
ein thereby titrating out limiting components of the
epressor complex (Weiss et al., 2003). c-Jun can itself
e the target of acetylation, at least under specific cir-
umstances. The MMP1 promoter can be activated by
-Jun, and repressed by the adenoviral E1A protein.
300 binds to E1A and repression of c-Jun induction
f MMP1 expression is dependent upon acetylation of
-Jun at Lys271 (Vries et al., 2001) A further report also
emonstrates that HDACi can suppress the expression
f c-jun and therefore the level of c-Jun protein. This
n turn leads to decreased binding of c-Jun to promoters
f cognate genes such as COX2 or MMP1 and therefore
DACi suppress the phorbol ester-induced expression
f these genes (Yamaguchi, Lantowski, Dannenberg,
Subbaramaiah, 2005). Data from the Clark labora-
ory align with this where TSA represses PMA-induced
MP1 expression in a number of cell lines (MRC5,
eLa, SW1353) (unpublished).
A recent paper suggests that Stats undergo acety-
ation at Lys 685 and that this is essential for their
imerisation and nuclear translocation (Yuan, Guan,
hatterjee, & Chin, 2005). In this case, the action of
DACi would increase acetylation and therefore potenti-
te Stat signaling. Whilst there are instances of this in the
iterature (e.g. the IL-4 induction of the 15-lipoxygenase-
gene, (42), more recent data appear to show the
pposite effect in the majority of cases. Thus, HDACi
ave revealed an essential role for HDACs in the tran-
cription of interferon-responsive genes (Genin, Morin,
Civas, 2003; Nusinzon & Horvath, 2003; Rascle,
ohnston, & Amati, 2003; Sakamoto, Potla, & Larner,
004) since such inhibitors repress IFN-stimulated gene
xpression.
As above, severalMMPgenes respond to proinflamm-
ory stimuli, at least in part, via the NFB pathway.
cetylation can impact upon this signaling pathway at aemistry & Cell Biology 40 (2008) 1362–1378 1371
number of levels. Firstly, NFB interacts with a number
of HATs (including CBP, p300, P/CAF) and HDACs to
impact upon gene expression. More specifically, HDACi
delay postinduction repression of NFB via prolonged
activity of IKK and therefore persistent degradation of
IB and delayed build up of cytoplasmic IB after an
inflammatory stimulus. The mechanism of this enhanced
IKK activity is unknown (Quivy & Van Lint, 2004). Fur-
ther, both p50 and p65, the most common components
of the NFB dimer can be acetylated at multiple lysine
residues. p50 acetylation increases DNA-binding affinity
and this correlates with induction of genes such as COX2
and iNOS (Quivy & Van Lint, 2004). There are oppos-
ing views of the outcome of p65 acetylation. Kiernan
et al. (2003) show that p65 acetylation reduces DNA-
binding affinity and enhances NFB removal from the
nucleus by IB and therefore abrogating NFB action.
Chen, Fischle, Verdin, and Greene (2001) and Chen, Mu,
and Greene (2002) show that p65 acetylation diminishes
binding to IB, allowing increased nuclear transloca-
tion of NFB and potentiation of signaling. They further
show that HDAC3 deacetylates p65 to abrogate signal-
ing and this fits with the ability of HDACi to potentiate
or prolong NFB signaling induced by TNF.
A number of other transcription factors relevant
to MMP gene expression are also subject to regula-
tion at the level of acetylation, including Sp1 and Sp3
and Ets family members (Ammanamanchi, Freeman, &
Brattain, 2003; Braun, Koop, Ertmer, Nacht, & Suske,
2001; Czuwara-Ladykowska, Sementchenko, Watson, &
Trojanowska, 2002; Yang & Sharrocks, 2004).
1.3. Methylation and MMP expression
In multicellular eukaryotes, DNA methylation is
restricted to cytosine bases with a number of known
DNA methyltransferases acting to methylate cytosines
within CpG dinucleotides. Methylation is usually asso-
ciated with a repressive chromatin state and inhibition of
gene expression. Methylation may block the binding of
transcriptional activators and/or methyl binding proteins
may recruit transcriptional repressors including HDACs
(Klose & Bird, 2006).
In lymphoma cells an inverse correlation was noted
between MMP9 promoter methylation and the level of
MMP9 expression (Chicoine et al., 2002). This was con-
firmed functionally with in vitro experiments. Similarly,
a colon cancer cell line in which the DNA methyl-
transferases Dnmt-1 and Dnmt-3b were knocked out,
show increased expression of MMP3 (but not MMP1 or
MMP2). Treatment of wildtype cells with DNA methyl
transferase inhibitors recapitulated this effect whilst in
f Bioch1372 I.M. Clark et al. / The International Journal o
vitro methylation of the MMP3 promoter suppressed its
activity (Couillard, Demers, Lavoie, & St-Pierre, 2006).
The induction of MMP3 by hypomethylation was also
shown to be cell-specific since in a lymphoma cell line
the methylase inhibitors showed no induction of MMP3,
but induction of MMP10. A further group (Shukeir,
Pakneshan, Chen, Szyf, & Rabbani, 2006) used the inva-
sive prostate cancer cell line PC-3, treated with a methyl
donor or antisense against methyl DNA-binding domain
protein 2. Both treatments led to the repression of MMP2
expression and decrease in tumour volume in vivo. Bisul-
fite sequencing was used to show that the 5′ region of the
MMP2 gene was methylated in response to the above
treatments.
In osteoarthritis, chondrocytes expressed increased
levels of MMP3, MMP9 and MMP13. Methylated CpG
sites were decreased across the promoters of these genes
with specific sites showing significantly higher demethy-
lation in each gene (Roach et al., 2005).
As mentioned above for TIMP3, a number of studies
demonstrate that silencing of TIMP genes via promoter
methylation as a feature of cancer cells e.g. (Yuan,
Jefferson, Popescu, & Reynolds, 2004). TheTIMP1 gene
is on the X chromosome and is thus subject to X chro-
mosome inactivation in females. Not all genes on the
inactive X chromosome are completely silenced and
TIMP1 is reported to display variable inactivation via
both methylation status and changes in chromatin struc-
ture (Anderson & Brown, 2005).
It is interesting to note that whilst the MMP genes
are distributed widely among the human chromosomes,
there is a cluster at 11q22 containing nine gene (MMP1,
MMP3, MMP7, MMP8, MMP10, MMP12, MMP13,
MMP20 andMMP27). The regulation of these genes may
require particular epigenetic features (chromatin marks
and/or structure) that are currently not understood.
1.4. mRNA stability and MMP expression
At the post-transcriptional level, gene expression can
be regulated via the stability of mRNA in the cytoplasm.
This is mediated via a variety of trans-acting factors
including both RNA-binding proteins and microRNAs
(miR) that interact with cis-elements located at many
sites in the mRNA. The most commonly described cis
element is the AUUUA sequence which is often found
in multiple copies within the 3′ UTR of mRNAs. Bind-
ing of protein factors to these elements can stabilize (e.g.
HuR) or destabilise (e.g. AUF1) such mRNAs (Garneau,
Wilusz, & Wilusz, 2007).
MMP and TIMP expression may be regulated (or per-
haps fine-tuned) at this level. Vincenti, White, Schroen,emistry & Cell Biology 40 (2008) 1362–1378
Benbow, and Brinckerhoff (1996) showed that the induc-
tion of MMP1 by IL-1 in rabbit synovial fibroblasts
required both transcriptional and post-transcriptional
components. In terms of the latter, the 3′ UTR of
the rabbit gene was able to destabilize a constitutively
expressed reporter. IL-1 treatment stabilized a cloned
human MMP1 transcript, as did mutation of ATTTA
motifs in the 3′ UTR. This demonstrates that, aside from
transcriptional activation, IL-1 increases MMP1 steady
state mRNA by countering the destabilizing effects of
the 3′UTR.
Similarly, cortisol induces MMP13 steady state
mRNA in osteoblasts by stabilizing transcripts (Rydziel,
Delany, & Canalis, 2004). Cortisol was shown to increase
protein binding to AU-rich elements in the MMP13
3′UTR. Studies using transgene reporters show that the
MMP13 3′UTR stabilizes a c-fos mRNA, with cortisol
further increasing mRNA stability in this system. Muta-
tion of theMMP13 3′UTR AU-rich elements destabilizes
c-fos transcripts compared to wild-type and blocks the
effects of cortisol. Both vinculin and far upstream ele-
ment (FUSE) binding protein 2 were shown to interact
with the MMP13 3′UTR and knockdown of these pro-
teins impacted upon MMP13 mRNA decay.
MMP9 expression can also be controlled at the level
of mRNA stability. In mesangial cells, the ATP ana-
log ATPS potentiates the ability of IL-1beta to induce
steady-state MMP9 mRNA. This effect is via three AU-
rich elements in the 3′ UTR of the MMP9 gene which
are constitutively bound in these cells by the RNA sta-
bilizing factor HuR. The binding of HuR-containing
complexes to these sites was increased by ATPS, and
the ATP-dependent effect on MMP9 UTR was abol-
ished by mutation in the three AURE (though this
had no effect on IL-1 induction itself) (Huwiler et al.,
2003). The same group identified a similar mechanism
for the ability of nitric oxide to reduce MMP9 steady
state mRNA. Recombinant HuR stabilized, whilst anti-
HuR antibody destabilized, the MMP9 mRNA. Nitric
oxide was shown to attenuate the expression of HuR
and its binding to the MMP9 3′UTR AU-rich elements
via a cGMP-dependent mechanism (Akool el et al.,
2003).
The TIMP3 3′ UTR was recently identified as a tar-
get for HuR binding in a screen of such mRNAs (Lal
et al., 2004). There are other reports of regulation of
TIMP mRNA stability, e.g. in astrocytes, regulation of
mRNA decay is reported to contribute to the downreg-
ulation of TIMP1 expression by IL-1 (Gardner et al.,
2006), however, molecular detail is yet to be described.
Micro RNAs (miRs) are small 21–25 nucleotide
RNAs that negatively regulate gene expression at the
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ost-transcriptional level, causing either inhibition of
ranslation or mRNA degradation. The numbers of iden-
ified miRs are growing rapidly, and there is speculation
hat as much as 30% of the human genome may be
ubject to regulation in this fashion (Lewis, Shih, Jones-
hoades, Bartel, & Burge, 2003). In cancer, miR profiles
oth identify the tissue of origin of tumours (Lu et
l., 2005), and are prognostic (Volinia et al., 2006).
ndividual miRs function as tumour suppressor genes
y regulating the expression of proto-oncogenes such
s Ras, or conversely examples such as miR-21 act
s oncogenes when over-expressed, by down-regulating
xpression of pro-apoptotic genes (Chan, Krichevsky, &
osik, 2005). To date little is known of the role of miRs
n regulation of cellular protease networks, but bioin-
ormatic analysis has indicated that several MMP and
IMP genes contain miR binding sites in their 3′UTRs,
ncluding MMP2 (miR-29), MMP14 (miR-24, miR-26
nd miR-181), TIMP2 (miR-30) and TIMP3 (miR-21,
iR-1/206 and miR-181) (Dalmay & Edwards, 2006).
ince TIMP3 is considered to be a tumour suppressor
unction that is often down-regulated in cancers, its pos-
ible regulation by miRs is intriguing and merits further
nvestigation.
.5. Promoter polymorphisms and MMP/TIMP
ene regulation
Single nucleotide polymorphisms are variations in
NA sequence common in the population which may
xist anywhere across a gene. Within gene promoters,
uch differences in genotype may alter promoter function
nd thus gene regulation.
The first single nucleotide polymorphism to be
escribed in an MMP gene promoter was the 5A/6A
NP at −1612 bp in MMP3 (Ye et al., 1996). This SNP
s within an interleukin-1 responsive element, with the
A allele driving greater expression in reporter assays.
he transcription factor ZBP89/ZNF148 and p65 con-
aining dimers of NFB all bind with similar affinity to
ither 5A or 6A allele, though p50 homodimers binds
ore effectively to the latter. This is hypothesized to act
s a transcriptional repressor by competing for other,
ctivating, NFB variants, though this has not been
xperimentally verified. This SNP associates with a num-
er of cardiovascular conditions (Ye, 2006).
Rutter et al. (1998) reported a SNP in the promoter
f the MMP1 gene at −1607 bp where an additional G
esidue creates an Ets binding site (5′GGAT3′ compared
o 5′GAT3′) adjacent to an AP-1 site at −1602 bp. The
G allele leads to higher levels of MMP1 expression
e.g. in A2058 melanoma cells) with evidence point-emistry & Cell Biology 40 (2008) 1362–1378 1373
ing to at least Fra-1 preferentially targeting transcription
from this allele (Tower, Coon, Belguise, Chalbos, &
Brinckerhoff, 2003). A variety of reports show asso-
ciation with either favourable (e.g. (Hettiaratchi et al.,
2007)) or unfavourable e.g. (Cao & Li, 2006; Zhu, Spitz,
Lei, Mills, & Wu, 2001) facets of cancer, though it should
be noted that a number of studies show no association
e.g. (Fong et al., 2004). Other pathologies have also
been examined, with e.g. Malik, Jury, Bayat, Ollier, and
Kay (2007) reporting that the 2G MMP1 genotype was
highly associated with aseptic loosening after total hip
replacement compared to controls.
A C to T SNP at −1562 bp in the MMP9 gene impacts
upon transcription of the gene. An unidentified nuclear
protein has higher affinity to the T-allele than the C-allele
with the former exhibiting higher activity in reporter
assays (Zhang et al., 1999). Studies in tissues from indi-
viduals suggest that this is replicated in vivo. The MMP9
promoter also contains a CA repeat region at approx
−131/−90 bp which can vary between 14 and 23 repeats.
Shorter repeat regions display reduced MMP9 promoter
activity, and this also correlates with expression of the
gene both lung and oesophageal cancer cell lines (Huang
et al., 2003; Shimajiri et al., 1999).
Functional SNPs in the MMP2 promoter include
a −1575 bp G to A polymorphism altering binding
of oestrogen receptor (Harendza et al., 2003) and a
−1306 bp C to T polymorphism altering binding of Sp1
(Price, Greaves, & Watkins, 2001). Other SNPs have
been described in the promoters of MMP7, MMP12 and
MMP13 (Ye, 2006).
Similarly to the MMP2 SNP described above, a
−418 bp G to C polymorphism abolishes an Sp1 site
in the TIMP2 promoter and this shows association with
COPD (Hirano et al., 2001) and some association with
breast cancer risk (Zhou et al., 2004). Two promoter vari-
ants in the TIMP3 gene, a −915 bp A to G and −1296 bp
T to C polymorphism, appear to contribute to susceptibil-
ity to the chronic lung disorder pigeon breeders disease
(Hill et al., 2004).
2. Conclusions
Unsurprisingly the regulation of the MMP and TIMP
gene families is complex. These genes are regulated
across development, in adult physiology and in disease.
In many situations, a number of genes within these fam-
ilies are being transcribed simultaneously, though such
subsets will differ depending on e.g. cell type and stimu-
lus. Hence, the combinatorial control of gene expression
at the promoter level can be coupled with epigenetic
control at the level of chromatin structure and post-
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transcriptional mechanisms, to give sufficient subtlety
to MMP and TIMP gene regulation. Our understanding
of these processes at the level of individual genes is rea-
sonably detailed in specific instances, however the future
challenge is to understand the regulation of the families at
a more global level. As high-throughput methodologies
are developed to study e.g. gene expression, structure
and transcription factor binding and activity, coupled
with appropriate in vivo promoter dissection, this will
eventually yield.
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